Loibl S, Reinisch M, Denkert C, Schneeweiss A, Seiler S, Fasching P, Hanusch C, Link T, Bjelic-Radisic V, Huober J, Untch M, Jackisch C, Solbach C, Blohmer JU, Rhiem K, Buechele T, Nekljudova V, Loi S (2022)
Publication Type: Conference contribution
Publication year: 2022
Publisher: KARGER
City/Town: BASEL
Pages Range: 38-39
Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT
DOI: 10.1016/j.annonc.2022.07.235
APA:
Loibl, S., Reinisch, M., Denkert, C., Schneeweiss, A., Seiler, S., Fasching, P.,... Loi, S. (2022). GeparPiPPa- A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC). In ONCOLOGY RESEARCH AND TREATMENT (pp. 38-39). BASEL: KARGER.
MLA:
Loibl, Sibylle, et al. "GeparPiPPa- A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2022. 38-39.
BibTeX: Download